BioCentury
ARTICLE | Clinical News

Eylea improves visual acuity in myopic choroidal neovascularization

June 7, 2013 12:57 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) jumped $22.53 (10%) to $252.17 on Thursday after the company and partner Bayer AG (Xetra:BAYN) said intravitreal Eylea aflibercept met the primary endpoint in the Phase III MYRROR trial to treat choroidal neovascularization (CNV) secondary to pathologic myopia. Eylea improved best corrected visual acuity (BCVA) as measured by the mean change from baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at week 24 vs. sham control (gain of 12.1 letters vs. a loss of 2 letters, p<0.0001). Patients in the Eylea arm were eligible to receive injections of the drug on an as-needed basis through 20 weeks, while patients in the sham control arm received monthly sham injections through week 20. The double-blind, Asian trial enrolled 122 patients with myopic CNV. Bayer, which has ex-U.S. rights to Eylea from Regeneron, plans to submit a regulatory application for Eylea to treat myopic CNV in Asia next half. ...